FMS vs LDOS vs HUM Stock Comparison

Fresenius Medical Care AG, Leidos Holdings and Humana Prices as of Oct 27, 2026 Peers: Industry group
1 more company in this comparison (MD) Create a free account to keep reading and compare up to 10 companies.
FMS Fresenius Medical Care AG
$22.50 -0.8% 1M -17.3% 1Y
Market cap
$12.57B
P/E
12.0x
Revenue (TTM)
$11.07B
Div. yield
3.82%
Healthcare Services Healthcare
5 wins
LDOS Leidos Holdings, Inc.
$139.65 +12.9% 1M -26.2% 1Y
Market cap
$17.52B
P/E
12.8x
Revenue (TTM)
$17.63B
Div. yield
1.23%
Defense Industrials
3 wins
HUM Humana Inc
$415.02 +4.2% 1M +42.0% 1Y
Market cap
$49.84B
P/E
39.0x
Revenue (TTM)
$145.68B
Div. yield
0.64%
Managed Care Healthcare
4 wins

Head to Head

12 decided of 12

Fresenius Medical Care AG leads on 5 of the 12 questions below (Fresenius Medical Care AG 5, Humana 4, Leidos Holdings 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionFMSLDOSHUMLeader
Larger companyMarket capitalisation $12.57B $17.52B $49.84B HUM
Cheaper on earningsLower P/E, profitable companies only 12.0x 12.8x 39.0x FMS
Cheaper on forward earningsLower price / next fiscal year consensus EPS 9.5x 11.0x 48.0x FMS
Faster revenue growthRevenue growth, trailing twelve months -47.8% +3.4% +18.3% HUM
More profitableNet margin, trailing twelve months 9.9% 7.8% 0.9% FMS
Better return on capitalReturn on invested capital 0.2% 13.9% 6.7% LDOS
Less leveragedLower net debt / EBITDA 200.7x 2.3x -2.7x HUM
Higher dividend yieldTrailing dividend yield 3.82% 1.23% 0.64% FMS
Better 1-year returnPrice return, last 12 months -17.3% -26.2% +42.0% HUM
Better 5-year returnAnnualised price return, 5 years -8.3%/yr +7.2%/yr -2.4%/yr LDOS
Less volatileAnnualised volatility, 1 year 31.1% 35.6% 48.0% FMS
Higher overall scoreMean of the five percentile scores vs peers 51/100 70/100 42/100 LDOS

Percentile Scorecard

FMSLDOSHUM

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisFMSLDOSHUM
Valuation 71 #27 of 92 98 #3 of 100 54 #12 of 25
Growth 12 #77 of 87 58 #41 of 97 13 #21 of 24
Profitability 64 #32 of 86 86 #14 of 96 39 #15 of 24
Financial Health 14 #84 of 97 33 #71 of 105 68 #9 of 26
Shareholder Returns 93 #5 of 56 75 #17 of 65 36 #10 of 15
Overall 51 70 42
  • FMS ranked among 102 companies in Healthcare Providers
  • LDOS ranked among 107 companies in Aerospace and Defense
  • HUM ranked among 27 companies in Healthcare Payers and Distributors

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodFMSLDOSHUMSPY
1 month -0.8%+12.9%+4.2% -0.2%
3 months -9.1%+18.0%+6.7% +3.9%
6 months 0.0%-4.4%+80.7% +8.2%
Year to date -5.5%-22.6%+62.0% +12.9%
1 year -17.3%-26.2%+42.0% +12.3%
3 years +37.2%+54.3%-18.7% +87.4%
3 years, per year +11.1%+15.6%-6.7% +23.3%
5 years -35.2%+41.7%-11.2% +67.9%
5 years, per year -8.3%+7.2%-2.4% +10.9%
10 years -44.4%+239.1%+138.3% +261.1%
10 years, per year -5.7%+13.0%+9.1% +13.7%

Risk

MeasureFMSLDOSHUMSPY
Volatility, 1Y 31.1%35.6%48.0% 12.7%
Downside volatility, 1Y 36.8%37.2%52.7% 12.7%
Beta vs S&P 500, 1Y 0.190.260.57 1.00
Return / volatility, 1Y -0.56-0.740.87 0.97
Max drawdown, 5Y -63.9%-50.3%-70.9% -25.4%
From 52-week high -17.3%-30.0%-4.3% -1.2%
52-week high $27.20$199.55$433.45 $779.14
52-week low $20.19$100.00$163.67 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleFMSLDOSHUM
P/E now vs peer median 12.0xmedian 24.6x 12.8xmedian 26.5x 39.0xmedian 23.9x
P/S now vs peer median 1.1xmedian 1.6x 1.0xmedian 3.0x 0.3xmedian 0.3x
EV/EBITDA now vs peer median 205.4xmedian 14.6x 9.8xmedian 14.6x 11.6xmedian 13.4x
P/FCF now vs peer median 6.0xmedian 21.6x 8.1xmedian 26.4x 25.6xmedian 15.5x
P/B now vs peer median 0.8xmedian 3.2x 3.3xmedian 2.5x 2.6xmedian 2.5x
PEG now vs peer median 0.57median 0.66 0.45median 0.90 -1.45median 1.34

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsFMSLDOSHUM
Revenue $11.07B $17.63B $145.68B
Gross profit -$5.62B $3.14B $19.89B
Operating income $879.32M $2.03B $2.71B
Net income $1.38B $1.40B $1.29B
Free cash flow $2.08B $2.16B $1.95B
R&D $180.01M – –
EPS (diluted) $1.79 $10.92 $10.56
Cash & equivalents $1.21B $748.00M $6.89B
Total debt $572.99B $21.66B $54.48B
Shares (diluted) 612.52M 126.00M 121.14M
Enterprise value $5.64B $14.29B -$37.96B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricFMSLDOSHUM
P/E 12.0x 12.8x 39.0x
P/FCF 6.0x 8.1x 25.6x
P/Operating cash flow 3.8x 7.6x 19.6x
P/S 1.1x 1.0x 0.3x
P/B 0.8x 3.3x 2.6x
P/Tangible book 0.9x 4.0x 2.6x
EV/EBITDA 205.4x 9.8x 11.6x
EV/EBIT 628.2x 11.2x 15.0x
EV/Revenue 49.9x 1.3x 0.3x
EV/FCF 265.6x 10.5x 20.8x
EV/Operating cash flow 167.5x 9.9x 16.0x
PEG (3Y EPS CAGR) 0.57 0.45 -1.45

Growth

14 metrics
MetricFMSLDOSHUM
Revenue growth (1Y) -47.8% 3.4% 18.3%
Revenue CAGR (3Y) -18.6% 5.9% 13.8%
Gross profit growth (1Y) -207.2% 4.8% 7.5%
Gross profit CAGR (3Y) -45.2% 14.4% 3.6%
Operating income growth (1Y) -45.5% -0.4% -17.9%
Operating income CAGR (3Y) -16.4% 21.1% -15.3%
Net income growth (1Y) 49.8% -0.8% -18.3%
Net income CAGR (3Y) 18.2% 24.8% -27.4%
EPS growth (1Y) 52.0% 1.3% -19.1%
EPS CAGR (3Y) 20.9% 28.6% -26.9%
Operating cash flow growth (1Y) 9.3% 54.9% -13.4%
Operating cash flow CAGR (3Y) 9.3% 35.7% -42.3%
Free cash flow growth (1Y) -7.7% 63.2% -20.1%
Free cash flow CAGR (3Y) 4.8% 41.7% -45.6%

Profitability

14 metrics
MetricFMSLDOSHUM
Gross margin -50.7% 17.8% 13.7%
EBITDA margin 24.3% 13.2% 2.4%
Operating margin 7.9% 11.5% 1.9%
Pretax margin 15.8% 10.2% 1.1%
Net margin 9.9% 7.8% 0.9%
FCF margin 18.8% 12.3% 1.3%
Operating cash flow margin 29.8% 13.0% 1.7%
Return on equity 2.7% 26.8% 6.8%
Return on assets 1.2% 9.0% 2.3%
Return on invested capital 0.2% 13.9% 6.7%
Return on capital employed 3.2% 16.5% 8.1%
Asset turnover 0.3x 1.1x 2.6x
Cash conversion (OCF / net income) 2.4x 1.6x 2.0x
Stock comp / revenue – 0.6% 0.2%

Financial Health

11 metrics
MetricFMSLDOSHUM
Debt / assets 1,515% 38.6% 25.5%
Debt / equity 35.0x 1.1x 0.8x
Net debt / EBITDA 200.7x 2.3x -2.7x
Debt / FCF 260.4x 2.8x 7.5x
Liabilities / assets 56.8% 65.9% 66.3%
Equity / assets 43.2% 34.1% 33.7%
Interest coverage 2.0x – 3.8x
Current ratio 1.1x 1.6x 1.7x
Quick ratio 0.2x 1.4x 1.3x
Cash ratio 0.2x 0.2x 1.0x
Altman Z-score 1.32 3.20 4.60

Shareholder Returns

7 metrics
MetricFMSLDOSHUM
Dividend yield 3.8% 1.2% 0.6%
Net buyback yield 8.6% 3.8% 0.3%
Shareholder yield 12.4% 5.0% 0.9%
Payout ratio (earnings) – 15.5% –
Payout ratio (FCF) – 10.0% –
Dividend growth (1Y) – 3.3% –
Dividend CAGR (3Y) – 2.8% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusFMSLDOSHUM
Forward P/E 9.5xFY2026 11.0xFY2026 48.0xFY2026
EPS, next fiscal year $2.37FY2026 $12.75FY2026 $8.65FY2026
EPS growth, next FY -6.0%FY2026 +6.3%FY2026 -49.5%FY2026
EPS growth, the year after +7.6% -9.0% +84.9%
Revenue, next fiscal year $21.50BFY2026 $17.52BFY2026 $166.70BFY2026
Revenue growth, next FY -7.0%FY2026 +2.0%FY2026 +28.6%FY2026
Revenue growth, the year after -0.3% +14.9% +7.6%
FMS estimates →LDOS estimates →HUM estimates →

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersFMSLDOSHUM
Held by institutions 7.3% 79.3% 98.6%
Institutions holding 235 773 927
Change in shares held, QoQ -2.9% +4.1% +2.7%
Institutions buying 151 380 558
Institutions selling 41 294 266
Buyers to sellers 3.68 1.29 2.10
FMS holders →LDOS holders →HUM holders →

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

FMSLDOSHUM
FMS 1.00 0.12 0.14
LDOS 0.12 1.00 0.09
HUM 0.14 0.09 1.00

Add a Peer

Largest companies in the same industry
FMS · Healthcare Services
+DVADavita +RDNTRadNet +CONConcentra Group Holdings Parent +LFSTLifeStance Health +SGRYSurgery Partners +PRVAPrivia Health +MDPediatrix Medical +PGNYProgyny
Plot all 36 Healthcare Services stocks → Plot all 68 Defense stocks → Plot all 8 Managed Care stocks →

Related Comparisons

FMS vs DVADavita FMS vs RDNTRadNet FMS vs CONConcentra Group Holdings Parent FMS vs LFSTLifeStance Health

Frequently Asked Questions

Which is bigger, FMS, LDOS and HUM?

Humana (HUM) is the largest by market capitalisation: Fresenius Medical Care AG (FMS) $12.57B, Leidos Holdings (LDOS) $17.52B, Humana (HUM) $49.84B.

Which stock is cheaper, FMS, LDOS and HUM?

Fresenius Medical Care AG (FMS) trades on the lowest price-to-earnings ratio (Fresenius Medical Care AG (FMS) 12.0x, Leidos Holdings (LDOS) 12.8x, Humana (HUM) 39.0x). On next year's consensus earnings, Fresenius Medical Care AG (FMS) is cheapest (Fresenius Medical Care AG (FMS) 9.5x, Leidos Holdings (LDOS) 11.0x, Humana (HUM) 48.0x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Humana (HUM) grew revenue fastest over the trailing twelve months: Fresenius Medical Care AG (FMS) -47.8%, Leidos Holdings (LDOS) +3.4%, Humana (HUM) +18.3%.

Which company is more profitable?

Fresenius Medical Care AG (FMS) has the highest net margin (Fresenius Medical Care AG (FMS) 9.9%, Leidos Holdings (LDOS) 7.8%, Humana (HUM) 0.9%). On return on invested capital, Leidos Holdings (LDOS) leads (Fresenius Medical Care AG (FMS) 0.2%, Leidos Holdings (LDOS) 13.9%, Humana (HUM) 6.7%).

Which stock has performed better?

Over the past year Humana (HUM) returned the most: Fresenius Medical Care AG (FMS) -17.3%, Leidos Holdings (LDOS) -26.2%, Humana (HUM) +42.0%. Over five years, Leidos Holdings (LDOS) compounded fastest (Fresenius Medical Care AG (FMS) -8.3%/yr, Leidos Holdings (LDOS) +7.2%/yr, Humana (HUM) -2.4%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Fresenius Medical Care AG (FMS) has the highest dividend yield: Fresenius Medical Care AG (FMS) 3.82%, Leidos Holdings (LDOS) 1.23%, Humana (HUM) 0.64%.

Which stock is riskier?

By one-year price volatility, Fresenius Medical Care AG (FMS) has been the steadiest (Fresenius Medical Care AG (FMS) 31.1%, Leidos Holdings (LDOS) 35.6%, Humana (HUM) 48.0%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, FMS, LDOS and HUM?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Fresenius Medical Care AG (FMS) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.